CMS delays star ratings for HealthCare.gov plans

The Centers for Medicare & Medicaid Services (CMS) released an announcement that it will further delay the star rating system intended to help patients make decisions when they shop for insurance on HealthCare.gov.

CMS planned to introduce the quality rating system in the federal insurance marketplace this fall for 2017, the fourth open enrollment is set for Nov. 1, 2016, to Jan. 31, 2017. With the delay they now intend to introduce the ratings by the time the fifth enrollment opens on Nov. 1, 2017.

The ranking system will include marks on access to care, how well doctors coordinate with enrollees and other doctors, whether the plan's network providers deliver care that achieves the best results, and how other enrollees rate their doctors and the care they receive.

Using the delay as a time to conduct further preliminary tests, the CMS will start evaluating the pilot launch taking place in some states, including Michigan, Ohio, Pennsylvania, Virginia and Wisconsin.

CMS announced at the beginning of the year that it planned to implement a star rating system to measure quality of healthcare of hospitals in the fall of 2016, and even with a study examining the star rating system and finding it lead to a lower risk of mortality and lower rate of admissions the system has been meet with skepticism. The rating system was also recently announced to be further delayed.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.